Signaling defects in anti‐tumor T cells
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Summary: The immune response to cancer has been long recognized, including both innate and adaptive responses, showing that the immune system can recognize protein products of genetic and epigenetic changes in transformed cells. The accumulation of antigen‐specific T cells within the tumor, the draining lymph node, and the circulation, either in newly diagnosed patients or resultant from experimental immunotherapy, proves that tumors produce antigens and that priming occurs. Unfortunately, just as obviously, tumors grow, implying that anti‐tumor immune responses are either not sufficiently vigorous to eliminate the cancer or that anti‐tumor immunity is suppressed. Both possibilities are supported by current data. In experimental animal models of cancer and also in patients, systemic immunity is usually not dramatically suppressed, because tumor‐bearing animals and patients develop T‐cell‐dependent immune responses to microbes and to either model antigens or experimental cancer vaccines. However, inhibition of specific anti‐tumor immunity is common, and several possible explanations of tolerance to tumor antigens or tumor‐induced immunesuppression have been proposed. Inhibition of effective anti‐tumor immunity results from the tumor or the host response to tumor growth, inhibiting the activation, differentiation, or function of anti‐tumor immune cells. As a consequence, anti‐tumor T cells cannot respond productively to developmental, targeting, or activation cues. While able to enhance the number and phenotype of anti‐tumor T cells, the modest success of immunotherapy has shown the necessity to attempt to reverse tolerance in anti‐tumor T cells, and the vanguard of experimental therapy now focuses on vaccination in combination with blockade of immunosuppressive mechanisms. This review discusses several potential mechanisms by which anti‐tumor T cells may be inhibited in function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · cited 20×
“They showed that binding between CTLA-4 on Tregs and B7-1 and B7-2 on DCs resulted in high levels of protein expression and enzymatic activity of IDO.”
BackgroundInfluentialUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 6×
“(103) suggests a role for IDO activity in the tumor environment itself as a mechanism of tumor immune evasion.”
BackgroundResultInfluentialShimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491 · cited 11×
“Piccirillo CA, et al. CD4(1)CD25(1) reg- ulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness.”
BackgroundInfluentialRelationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism
Taylor, M. W., & Feng, G. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907934 · Cited by 1,060
Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo
Meng, T.-C., Fukada, T., & Tonks, N. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00445-8 · Cited by 1,040
Brown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968 · cited 2×
“For example, one ligand for an immunoreceptor-signaling receptor (PD-1) is B7H1, which is expressed on some types of DCs (155, 156), placental trophoblasts (157), and certain epithelial cells (158).”
BackgroundHIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
Appay, V., Nixon, D. F., Donahoe, S. M., Gillespie, G. M. A., Dong, T., King, A., Ogg, G. S., Spiegel, H. M. L., Conlon, C., Spina, C. A., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.63 · Cited by 871 · cited 1×
“The reversibility of lytic dysfunction is distinct from other defects in CD8(1) T cells that have been described: deficient maturation of CD8(1) T cells in human immunodeficiency virus infection (150) or hyporesponsiveness due to imprinting (as described for lamina propria T cells) (151).”
BackgroundMunn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852 · cited 16×
“In murine tumor models, a novel subset of pDCs (CD11c1CD191 B2201) expresses functional IDO and has been found at increased levels in tumor-draining LNs (125).”
BackgroundInfluentialRegulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo
Chen, M.-L., Pittet, M. J., Gorelik, L., Flavell, R. A., Weissleder, R., von Boehmer, H., & Khazaie, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408197102 · Cited by 806
Cited by
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Calcinotto, A., Filipazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., Cova, A., Canese, R., Jachetti, E., Rossetti, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1272 · Cited by 640
“Together with defects in perforin degranulation and cytokine secretion (30), these features are reminiscent of those detected in TILs analyzed ex vivo or in circulating CD3þ T cells of advanced disease patients (3).”
BackgroundMechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells
Nagaraj, S., Schrum, A. G., Cho, H.-I., Celis, E., & Gabrilovich, D. I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902661 · Cited by 414
Verma, V., Shrimali, R. K., Ahmad, S., Dai, W., Wang, H., Lu, S., Nandre, R., Gaur, P., Lopez, J., Sade-Feldman, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0441-y · Cited by 333
What are regulatory T cells (Treg) regulating in cancer and why?
Whiteside, T. L. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.03.004 · Cited by 291
Metadata
- Authors
- Frey, A. B., & Monu, N.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2008-03-19
- Volume
- 222
- Issue
- 1
- Pages
- 192-205
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W1980484335
- Cited by
- 90
- References
- 14
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Signaling defects in anti‐tumor T cells. https://app.cochat.ai/papers/10.1111/j.1600-065x.2008.00606.x
- The paper
- Frey, A. B., & Monu, N. (2008). Signaling defects in anti‐tumor T cells. Immunological Reviews. https://doi.org/10.1111/j.1600-065x.2008.00606.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.